Expert Review of Neurotherapeutics

Papers
(The H4-Index of Expert Review of Neurotherapeutics is 21. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Does electrical stimulation still have a place in the treatment armamentarium for Bell’s palsy?46
How have the recent updated epilepsy classifications impacted on diagnosis and treatment?42
The role of Fecal Microbiota Transplantation (FMT) in treating patients with multiple sclerosis38
Neonatal seizures treatment based on conventional multichannel EEG monitoring: an overview of therapeutic options36
Profiling deutetrabenazine extended-release tablets for tardive dyskinesia and chorea associated with Huntington’s disease34
An overview of the differences in the pharmacological management of post-traumatic stress disorder between women and men31
The latest developments with internet-based psychological treatments for depression30
Laser interstitial thermal therapy for recurrent brain metastases following stereotactic radiosurgery: a systematic review29
The relevance of cortical thickness in migraine sufferers and implications to therapy28
Determining minimally clinically important differences for outcome measures in patients with chronic motor deficits secondary to traumatic brain injury27
Where Art Thou O treatment for diabetic neuropathy: the sequel27
Ultrasensitive techniques and protein misfolding amplification assays for biomarker-guided reconceptualization of Alzheimer’s and other neurodegenerative diseases25
Immunomodulatory effects and clinical benefits of intravenous immunoglobulin in myasthenia gravis24
The influence of anxiety and depression on headache in adolescent migraineurs: a case-control study24
Neuroprotective strategies in multiple sclerosis: a status update and emerging paradigms23
Advances in the treatment and management of frontotemporal dementia22
Viloxazine extended-release capsules as an emerging treatment for attention-deficit/hyperactivity disorder in children and adolescents21
The current status of somatostatin analogs in the treatment of neuroendocrine tumors and future perspectives21
Uncertainties in anti-amyloid monoclonal antibody therapy for Alzheimer’s disease: the challenges ahead21
Updated review on the link between cortical spreading depression and headache disorders21
Why is ADHD so difficult to diagnose in older adults?21
0.03678297996521